Cogent Biosciences Q3 net loss widens on higher expenses
COGT•Cogent Biosciences’ third-quarter net loss widened to $111.43 million as expenses rose. The company said its $791.1 million cash balance is expected to fund operations into late 2028.
1. Quarterly results
Cogent Biosciences reported a third-quarter net loss of $111.43 million and operating expenses of $117.18 million. Research and development expenses increased due to ongoing SUMMIT, PEAK and APEX trials and early-stage pipeline programs, while general and administrative costs rose with commercial-readiness investments and organizational growth.
2. Approval outlook
The company expects potential FDA approval of bezuclastinib for GIST by November 30, 2026, for NonAdvSM by December 30, 2026, and for AdvSM by June 29, 2027. Its $791.1 million cash balance is expected to fund operations into late 2028.
